Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Share News (CIR)

  • There is currently no data for CIR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 250 movers: Broker notes spur on big movers

Tue, 15th Dec 2015 15:24

(ShareCast News) - The FTSE 250 looks to finish the day in the green, with the second-tier market up 228.85 point (1.36%) to 17,001.42 mid-afternoon Tuesday. Circassia Pharmaceuticals rose to the top of the ranks after RBC Capital Markets initiated coverage at 'top pick' for the company. "With intrinsic value still almost wholly aligned to its immunotherapy assets and the first set to produce Phase 3 data in 1H 2016, we think investors should buy ahead of this newsflow given impressive prior P2b data and as investor doubts about trial success have provided for a healthy risk/reward profile," a note from the investment bank said. It said news about its lead immunotherapy drug CAT-SPIRE in the first half of 2016 should act as a catalyst for the stock, and that there's a further potential newsflow in 2017 that could see a further re-rating.RBC Capital Markets also initiated coverage on the market's second biggest riser, BTG, at 'outperform' with a price target of 820p, saying it should be a long-term holding. It said share in the specialist pharmaceutical company have underperformed materially over the past year and, while medium-term market expectations are still ambitious, the potential near-term approval of RePneu in the US and BTG's long-term growth prospects are fundamental reasons to own the stock. RBC said the stock weakness has been almost entirely associated with the weak launch of the company's varicose vein product, Varithena, but now presents an opportunity as the factors behind the selloff are being resolved and are short term. "Given the advantages of this product over current technologies, we continue to believe Varithena could exceed management's $500m revenue target," it said.The rebound in oil prices has also boosted a number of second-tier stocks. Earlier in the day West Texas Intermediate crude was up 1.43% to $36.83, while Brent crude also rose 1.58% to $38.52 a barrel. That forced Tullow Oil shares up over 5% on the day.Aveva Group was the day's biggest faller, plunging over 28% on news it had terminated takeover talks with French suitor Schneider Electric after the pair were unable to reach agreement. The engineering software group said that during the due diligence process, the two companies identified "significant integration challenges" that they did not feel could be overcome without considerable additional risk and cost. Aveva had previously commented that Schneider Electric and Schneider Software shared backoffice and property resources, and that separating these would be no small task. As a result, it was decided that the combination would be unlikely to deliver the anticipated uplift in shareholder value.FTSE 250 - RisersCircassia Pharmaceuticals (CIR) 301.00p 9.26%BTG (BTG) 670.00p 7.46%Evraz (EVR) 62.30p 6.04%Tullow Oil (TLW) 160.70p 5.65%Investec (INVP) 456.00p 5.51%AA (AA.) 283.90p 5.30%RPC Group (RPC) 821.00p 4.92%Thomas Cook Group (TCG) 118.50p 4.87%UBM (UBM) 494.90p 4.61%Henderson Group (HGG) 289.30p 4.25%FTSE 250 - FallersAveva Group (AVV) 1,548.00p -28.53%Home Retail Group (HOME) 95.40p -7.20%Supergroup (SGP) 1,510.00p -6.73%Foxtons Group (FOXT) 178.40p -4.34%Domino's Pizza Group (DOM) 962.00p -3.46%Paragon Group Of Companies (PAG) 346.80p -3.16%Keller Group (KLR) 792.50p -3.00%Serco Group (SRP) 94.10p -2.69%Halfords Group (HFD) 334.00p -2.68%Virgin Money Holdings (UK) (VM.) 371.20p -2.37%
More News
22 Jul 2014 15:14

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
18 Jun 2014 09:03

Wednesday broker round-up UPDATE

Ashtead Group: Barclays ups target price from 930p to 946p retaining its overweight rating. Berkeley Group: Numis upgrades from hold to buy with a target price of 2491p. Brown (N) Group: Oriel places its buy recommendation under review. BT Group: Jefferies ups target price from 440p to 470p and k

Read more
13 Jun 2014 08:45

Circassia Pharmaceuticals Sees Positive Results From Allergy Study

LONDON (Alliance News) - Circassia Pharmaceuticals PLC said Friday it has seen positive results from a two-year follow up of a phase IIb study of a house dust mite allergy product HDM-SPIRE. Investigators reassessed patients' allergy symptoms two years after starting treatment with the prod

Read more
2 Jun 2014 09:13

Imperial Innovation Looks To Raise GBP150.0 Million In Share Placing

LONDON (Alliance News) - Imperial Innovations Group PLC Monday detailed plans to raise up to GBP150.0 million before expenses through a share placing with new and existing investors, as it looks to support its existing portfolio companies, source opportunities to invest in new technologies, and f

Read more
19 May 2014 13:11

Circassia Pharmaceuticals Funded To Progress With Allergy Treatments

LONDON (Alliance News) - Clinical-stage specialty biopharmaceutical company Circassia Pharmaceuticals PLC Monday said it is fully-funded to continue the development of its SPIRE product portfolio and bringing CAT-SPIRE to the market after raising over GBP200 million though an initial public offer

Read more
21 Mar 2014 15:31

IPO Statistics: London Main Market 2014

Read more
18 Mar 2014 17:05

DIRECTOR DEALINGS: Circassia Phamaceuticals CEO, Non-Executive Transfer Shares

LONDON (Alliance News) - Circassia Pharmaceuticals PLC Tuesday said Chief Executive Steven Harris and non-executive Director Charles Swingland transfered shares into family trusts Thursday.

Details are as follows.

Read more
18 Mar 2014 14:00

Dalata Hotel Group IPO Oversubscribed

LONDON (Alliance News) - Dalata Hotel Group PLC Tuesday said it has raised EUR265 million gross through a placing of 106 million shares under its float on AIM, with the net proceeds earmarked for the acquisition of a portfolio of 16 to 25 hotels throughout Ireland and to pay down its debt.

Read more
13 Mar 2014 10:04

Circassia Pharmaceuticals hails 'biggest ever' UK biotech IPO

Allergy treatment developer Circassia Pharmaceuticals has confirmed it is raising 200m pounds in its initial public offering, as conditional trading between brokers began on Thursday morning. The biotech firm, which was spun out of university technology transfer group Imperial Innovations, priced

Read more

Quickpicks are a member only feature

Login to your account